AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06003309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - targeted-iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
Study NCT06003309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - Standard-iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
Study NCT06111521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally
Study NCT06111521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study NCT05102448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.
Study NCT05102448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.
Study NCT03327129 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI
Description: An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
Study NCT06111521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally
Study NCT06111521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally
Study NCT06111521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered IV
Study NCT04949464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo LDCT
Study NCT04949464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Use Positively Smoke Free - Mobile
Study NCT05314478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous laryngoscopy during exercise test using the HALOS headgear
Description: The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored.
Study NCT05515198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patients will be provided educational opportunities.
Study NCT05515198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigation
Description: A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
Study NCT05515198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChatBot
Description: A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms.
Study NCT06070441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
Study NCT06070441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
Study NCT06070441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: 12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
Study NCT06070441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise, usual care
Description: 12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
Study NCT05343000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (PR) system
Description: Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
Study NCT05685758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FTP-based therapeutic mobile-app
Description: Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
Study NCT05436275 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CM310
Description: 300 mg every two weeks
Study NCT05436275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once every two weeks
Study NCT06406790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CraniSeal
Description: CraniSeal is a PEG Dural Sealant
Study NCT06406790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal
Description: DuraSeal is a PEG Dural Sealant
Study NCT05054036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: Split-dose MoviPrep bowel preparation
Study NCT05054036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: Split-dose GoLYTELY bowel preparation
Study NCT04758078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Description: Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
Study NCT04758078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized 0.9% saline will be given four times per day
Study NCT05152563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
Study NCT05575440 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo a PET/CT scan
Study NCT05575440 — intervention group
Intervention type: RADIATION
Intervention: Fluorine F 18 Tetrafluoroborate
Description: Given IV
Study NCT05575440 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo a PET/CT scan
Study NCT05575440 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05152563 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT05821673 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Argon plasma pre-treated abutment insertion
Description: abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
Study NCT05821673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon plasma pre-treated abutment insertion
Description: abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
Study NCT05821673 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: abutment insertion
Description: the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
Study NCT05998668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genital hygiene training
Description: In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
Study NCT05136131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Description: Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion.
Study NCT05136131 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electrical cardioversion
Description: No shock is delivered in the sham procedure arm.
Study NCT06412575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: JNT Guided OGT-overlap Oesophagojejunostomy
Description: In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
Study NCT06412575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TNT Guided OGT-overlap Oesophagojejunostomy
Description: In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
Study NCT05258630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Homeless Medication Support (D-Homes)
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
Study NCT05258630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
Study NCT05258630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
Study NCT04736862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring
Description: In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
Study NCT04736862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent non-invasive blood pressure monitoring
Description: In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
Study NCT05221307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
Study NCT05221307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
Study NCT06093204 — intervention group
Intervention type: OTHER
Intervention: Dietary evaluation
Description: Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
Study NCT04433533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
Study NCT04433533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe 10/10
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
Study NCT04656236 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 3-hydroxybutyrate
Description: 3-hydroxybutyrate is a metabolite, produced in the human body.
Study NCT04656236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate
Description: 3-hydroxybutyrate is a metabolite, produced in the human body.
Study NCT05044000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep propioceptive stimulation
Description: Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
Study NCT05044000 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep propioceptive stimulation
Description: Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
Study NCT06488313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR Lotion - AMP Human Performance
Description: Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PR Lotion - AMP Human Performance
Description: Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers >2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lotion
Description: Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AminoVital - Rapid Recovery
Description: AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AminoVital - Rapid Recovery
Description: AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
Study NCT05092854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Supplement
Description: Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.